NIAID Launches First Phase II Trial of a "Global" HIV/AIDS Vaccine
AIDS HIV Vaccine
A novel vaccine targeted to multiple HIV subtypes found worldwide has moved into the second phase of clinical testing, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced today. The study investigators plan to enroll a total of 480 participants at sites in Africa, North America, South America, and the Caribbean to test the safety and immune response to the vaccine.
The experimental vaccine was developed by scientists at NIAID's Dale and Betty Bumpers Vaccine Research Center (VRC) and is being studied in the HIV Vaccine Trials Network (HVTN), a clinical research collaboration funded by NIAID's Division of AIDS (DAIDS).
"This trial marks an important step in the advancement toward an AIDS vaccine. The rapid development of this candidate vaccine